Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 12/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | HINT1 | P49773 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7764877 | 1.00 | TYMP (0.60) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL1582054 | 0.95 | TYMP (0.60) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL3313773 | 0.95 | TYMP (0.60) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL18954969 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL21160998 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL18954966 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL21160996 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL19493329 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL17304337 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL7267975 | 0.94 | TYMP (0.57) | TYMPTAS1R3TAS1R1KDM4ENT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | TYMP 2973/4885TAS1R3 201/4885TAS1R1 124/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | TYMP 3035/4885TAS1R3 212/4885TAS1R1 134/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | TYMP 2997/4885TAS1R3 194/4885TAS1R1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.